The largest database of trusted experimental protocols

Cytosnp850k array

Manufactured by Illumina

The CytoSNP850K array is a high-throughput genotyping platform developed by Illumina. It enables the detection and analysis of genetic variations across the human genome. The core function of this product is to provide a comprehensive assessment of single nucleotide polymorphisms (SNPs) and copy number variations (CNVs) in a single experiment.

Automatically generated - may contain errors

6 protocols using cytosnp850k array

1

Validation of Genomic Profiling Techniques

Check if the same lab product or an alternative is used in the 5 most similar protocols
For the validation, two types of samples were used: 1) HapMap DNA samples and 2) genomic DNA isolated from FFPE tissue (tumor and normal) from the following cancer types: breast, ovarian, uterine, colon, kidney, liver, melanoma, head and neck. All FFPE specimens had been previously characterized by either Illumina CytoSNP850K array, Sanger Sequencing, NGS panel (FoundationOne, Guardant Health or Caris), OncoScan hotspot panel, FISH, CISH, IHC, qPCR or multiple methods. In addition, a matched blood sample was included when available. All FFPE specimens were reviewed by a pathologist and contained ≥ 20% tumor cellularity.
+ Open protocol
+ Expand
2

Characterization of Induced Pluripotent Stem Cells

Check if the same lab product or an alternative is used in the 5 most similar protocols
Induced PSCs were stained for nanog, OCT4, SOX2 and SSEA-4. For pluripotency analysis, iPSCs were allowed to differentiate spontaneously in mTeSR-1 media or randomly differentiated using the Human Pluripotent Stem Cell Functional Identification Kit (#SC027; R&D Systems) and stained for markers of the three germ layers. All iPSCs generated cells of all three germ layers, assessed by positive immunoreactivity for β-III-tubulin for ectoderm, smooth muscle actin for mesoderm and SOX17 for endoderm. For the array CGH, DNA was extracted using the QIAamp DNA Blood Mini kit (Qiagen) according to manufacturer’s protocol and eluted in nuclease-free water. Eluted DNA was processed for analysis by Illumina CytoSNP 850K array per manufacturer protocol. Data was processed and CNV calls generated with BlueFuse Multi Software v4.2 (Illumina). CNV calls by SNP array were reported using standard clinical thresholds in the UCSF Clinical Cytogenetics Laboratory, including annotation of any CNVs >200kb. Interpretation of clinical significance was done per standard American College of Medical Genetics guidelines (Kearney et al., 2011 (link)). See Table S2 for array CGH results.
+ Open protocol
+ Expand
3

Comprehensive Genetic Analysis of Hematological Disorders

Check if the same lab product or an alternative is used in the 5 most similar protocols
Karyotype chromosome analysis completed via bone marrow aspirate samples. Microarray analysis performed using the Affymetrix Cytoscan HD platform to identify DNA copy number gains/losses and regions of loss of heterozygosity [6 ]. Peripheral blood chromosomal microarray (CMA) analysis completed using the Illumina CytoSNP-850 K array, with aberrations confirmed by qPCR [7 ].
Screening for underlying germline inborn errors of immunity variants was completed via next-generation exome sequencing through Blueprint Genetics (642 gene Comprehensive Immune and Cytopenia Panel) [8 ].
+ Open protocol
+ Expand
4

DNA Extraction and CNV Analysis

Check if the same lab product or an alternative is used in the 5 most similar protocols
DNA was extracted from HEK293T or iPSC samples using QIAgen miniprep kit and quantified by Nanodrop (Thermo Fisher). DNA was processed for analysis by Illumina CytoSNP 850 K array according to the manufacturer’s protocol. Data were processed, and CNV calls were generated with BlueFuse Multi Software v4.2 (Illumina). CNV calls by SNP array were reported using standard clinical thresholds in the University of California San Francisco Clinical Cytogenetics Laboratory, including annotation of any CNVs > 500 kb. Interpretation of clinical significance was done according to standard American College of Medical Genetics guidelines25 (link).
+ Open protocol
+ Expand
5

Paired-end Exome Sequencing of Lesional Skin

Check if the same lab product or an alternative is used in the 5 most similar protocols
For the paired-end pre-capture library procedure, genomic DNA from a lesional skin and blood was fragmented by sonication and ligated to the Illumina multiplexing paired-end (PE) adapters. The adapter-ligated DNA was then polymerase chain reaction (PCR) amplified using primers with sequencing barcodes (indexes). For target enrichment/exome capture procedure, the pre-capture library was enriched by hybridizing to biotin labeled VCRome 2.1 in-solution exome probes (Bainbridge et al., 2011 (link)) for 64–72 h at 47°C. Additional probes for over 3600 Mendelian disease genes were also included in the capture in order to improve the exome coverage. For massively parallel sequencing, the post-capture library DNA was subjected to sequence analysis on Illumina HiSeq platform for 100-bp paired-end reads. The following quality control metrics of the sequencing data are generally achieved: >70% of reads aligned to target, >95% target base covered at >20X, >85% target base covered at >40X, mean coverage of target bases >100X. Single-nucleotide polymorphism (SNP) concordance to genotype array: >99%. As a quality control measure, DNA was also analyzed by a SNP array: Illumina Human Exome-12v1 array and the Illumina CytoSNP-850K array. The SNP data are compared with the WES data to ensure correct sample identification and to assess sequencing quality.
+ Open protocol
+ Expand
6

Genome-wide Copy Number Variant Analysis

Check if the same lab product or an alternative is used in the 5 most similar protocols
DNA was extracted from EDTA preserved peripheral blood using the QIAGEN QIASymphony DNA Midi Kit or Chemagen blood 4K DNA Extraction kit. Patient’s DNA samples were amplified, fragmented, and hybridized to the Illumina beadchip array (CytoSNP 850K Array), followed by single base extension, in order to determine the genotype and copy number status for each locus as per the Illumina Infinium HD assay protocol. Results were analysed with BlueFuse Multi version 4.4, using genome reference sequence GRCh37/hg19. The effective resolution was 200 kb. The copy number variants that meet the internal laboratory reporting criteria were classified using the 2020 ClinGen/ACMG standards [20 (link)] for the interpretation and reporting of constitutional copy number variants.
If a Variant of Uncertain Significance (VUS) was identified from the CMA, the clinical significance was determined by assessing phenotypes of reported cases with similar copy number variants, the gene content, the correlation between those genes and the phenotype, and whether evidence existed to suggest that duplication or deletion of an encompassed gene was a pathogenic mechanism. In cases where the variant was plausibly related to the presentation, further evidence was sought through segregation studies.
+ Open protocol
+ Expand

About PubCompare

Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.

We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.

However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.

Ready to get started?

Sign up for free.
Registration takes 20 seconds.
Available from any computer
No download required

Sign up now

Revolutionizing how scientists
search and build protocols!